STOCK TITAN
  1. Home
  2. News
  3. WINT

Windtree Therapeutics Inc - WINT STOCK NEWS

Welcome to our dedicated news page for Windtree Therapeutics (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Windtree Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Windtree Therapeutics's position in the market.

News
Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024
Rhea-AI Summary
Windtree Therapeutics, Inc. (NASDAQ:WINT) has started phase 2 SEISMiC Extension Study for istaroxime in early cardiogenic shock treatment, aiming to build on positive SEISMiC study data and facilitate the end-of-phase 2 meeting with the FDA. Cardiogenic shock has a high mortality rate and unmet need for drug treatment. Market research shows the potential for istaroxime, with 84% of cardiologists willing to use it. Istaroxime has already shown positive results in treating cardiogenic shock, and the SEISMiC Extension Study is expected to pave the way for a phase 3 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
clinical trial
-
News
Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
Rhea-AI Summary
Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced the enrollment of the first subject in its Phase 2 SEISMiC Extension Study of istaroxime in the treatment of early cardiogenic shock. The study results are expected in mid-2024. The company is also progressing a parallel SCAI Stage C Phase 2 study with istaroxime in cardiogenic shock targeting data in a similar timeframe. This extension study aims to evaluate a longer dosing cycle of istaroxime and gather data to characterize the potential benefits of SERCA2a activation in these patients, advancing the company’s clinical and regulatory position for potential Phase 3 readiness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent
Rhea-AI Summary
Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced the granting of Patent No. 3805243 by the European Patent Office, providing coverage for the pure SERCA2a Activator class of drug candidates. These activators are intended for the treatment of heart failure and are devoid of action on the Na+/K+ pump. The new patent provides protection until October 9, 2039 for compounds with the pure SERCA2a mechanism of action. This development is significant for the chronic out-patient and hospital markets, with the potential to benefit nearly half of the chronic heart failure patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
none
News
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
Rhea-AI Summary
Windtree Therapeutics, Inc. (WINT) reported financial results for Q3 2023, including a net loss of $4.4 million. The company made progress with the istaroxime program and next-generation SERCA2a activators, and announced a new composition of matter patent. Cash and cash equivalents as of September 30, 2023, were $7.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
earnings
-
News
Windtree to Present at the Sidoti Micro Cap Conference on November 16th
Rhea-AI Summary
Windtree Therapeutics, Inc. (WINT) to present corporate update at Sidoti Micro Cap Conference, offering virtual 1x1 meetings with investors. Craig Fraser, President and CEO, to speak on late-stage interventions for cardiovascular disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
conferences
-
News
Windtree to Present at the ThinkEquity Conference on October 19th in New York City
Rhea-AI Summary
Windtree Therapeutics to present at ThinkEquity Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.42%
Tags
conferences
News
Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th
Rhea-AI Summary
Windtree Therapeutics to participate in panel discussion at Lytham Partners Fall 2023 Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
conferences
-
News
Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th
Rhea-AI Summary
Windtree Therapeutics to present at Dawson James Small Cap Growth Conference on October 12, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
conferences
-
News
Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office
Rhea-AI Summary
Windtree Therapeutics receives US patent for dual mechanism SERCA2a Activators, providing patent protection through late 2039. The company plans to position these compounds as a 'fast follow-on' to istaroxime, offering potential oral bioavailability for the treatment of chronic heart failure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
none
News
Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market
Rhea-AI Summary
Windtree Therapeutics (NASDAQ:WINT) is a biotechnology company developing treatments for severe cardiovascular disorders. Its leading drug candidate, istaroxime, has completed three positive phase 2 trials. Windtree aims to develop a next-generation family of drugs for heart failure, including dual-mechanism and pure SERCA2a activators. The company recently raised $12.4 million and received patent coverage for its dual mechanism SERCA2a activators.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.32%
Tags
none
Stock WINT logo
Windtree Therapeutics Inc

Nasdaq:WINT

WINT Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

WINT Stock Data

3.99M
4.55M
4.65%
12.91%
0.43%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Warrington

About WINT

windtree therapeutics, inc. is a biotechnology company focused on developing novel kl4 surfactant therapies for respiratory diseases and other potential applications. windtree’s proprietary technology platform includes a synthetic, peptide-containing surfactant (kl4 surfactant ) that is structurally similar to human pulmonary surfactant — and novel drug-delivery technologies that are being developed to enable noninvasive administration of aerosolized kl4 surfactant. windtree is focused initially on improving the management of respiratory distress syndrome (rds) in premature infants as surfactant therapy has been shown to save lives in this condition. windtree believes that its proprietary technologies may make it possible, over time, to develop a pipeline of kl4 surfactant product candidates to address a variety of respiratory diseases for which there are few or no approved therapies and, in doing so, potentially deliver a lifetime of hope to patients and their families.